Satellite: Novartis Spain Symposium: 00 – 00: Diabetic Macular Oedema



Download 26.77 Kb.
Date conversion21.06.2018
Size26.77 Kb.
EASDEC 2013 Programme

23rd May 2013, Thursday

Satellite: Novartis Spain Symposium:

4.00 – 7.00: Diabetic Macular Oedema

Chaired by: Professors José García-Arumí and Rafael Simó

The official programme of EASDec starts with:

7.00: Opening ceremony followed by refreshments



24th May 2013: Friday

8.30 – 9.00: Registration

9.00 – Introduction and welcome Professor Rafael Simó

Session 1: Roundtable 1: New Perspectives in the Treatment of Diabetic Macular Oedema

Chairs: Professors Jose García-Arumi and Gabriele E. Lang

9.15 – 9.35: Diabetologists’ view: Professor Javier Salvador, President of the Spanish Society of Endocrinology

9.35 – 9.55: Ophthalmologists’ view: Professor Pascale Massin, Paris, France

9.55 – 10.15: Discussion and chairman summary

10.15 – 10.30: Overexpression of hemopexin in the diabetic eye: a new pathogenic candidate for diabetic macular edema. M. Garcia-Ramírez, C. Hernández, R. Simó

10.30 – 10.45: Development of a new blood-retinal barrier model in vitro. A. Van der Wijk, J. Wisniewska-Kruk, I. Klaassen, R.O. Schlingemann

10.45 – 11.00: Molecular characterisation of the inner blood-retinal barrier in the akimba mouse, a new model of diabetic retinopathy. I. Klaassen, J. Wisniewska-Kruk, I.M.C. Vogels, C.M. Lai, C.J.F. Van Noorden, R.O. Schlingemann, E.P. Rakoczy

11.00 – 11.20: In memoriam Professor Anne Katrin Sjolie presented by Massimo Porta

Best abstract prize: The role of plasmalemma vesicle-associated protein in blood retinal barrier permeability. J. Wisniewska-Kruk, I. Klaassen, I.M.C. Vogels, C.J.F. Van Noorden, R.O. Schlingemann

11.20 – 11.45: Coffee/tea, exhibitions

Session 2: Laboratory and Clinical Biomarkers of Diabetic Retinopathy

Chairs: Professor Reiner Schlingermann and Professor Jose Cunha-Vaz

11.45 – 12.00: Aqueous humor biomarkers of retina macroglia activation in diabetic patients. S. Vujosevic, M. Berton, S. Bini, A. Micera, G. Esposito, O. Kotsafti, E. Midena

12.00 – 12.15: Retinal inflammation biomarkers in patients with diabetic retinopathy. E. Midena, G.. Midena, S. Bini, M. Berton, R. Parrozzani, O. Kotsafti, S. Vujosevic

12.15 – 12.30: Microaneurysm turnover predicts risk of development of clinically significant diabetic macular oedema. L. Ribeiro, S. Nunes, J. Cunha-Vaz

12.30 – 12.45: Microaneurysm-count as a predictor of progression of retinopathy in patients with type 1 diabetes? M. L. Rasmussen, R.B. Pedersen, T. Peto, J. Grauslund

12.45 – 1.00: Patterns of progression in diabetic retinopathy: correlation between phenotypes and genotypes. S. Nunes, C. Lobo, L. Ribeiro, I. Pires, M.J. Simões, C. Faro, J. Cunha-Vaz

1.00 – 1.15: Obstructive sleep apnoea is associated with sight threatening retinopathy and predicts the development of preproliferative and proliferative retinopathy in patients with type 2 diabetes: a longitudinal analysis. A. Tahrani, P. Dodson, A. Ali, Q. Altaf, H. Wharton, N. T. Raymond, M. J. Stevens

1.15 – 2.00: Lunch and Exhibition viewing

1.30 – 3.00:



Session 3: Poster Session

Moderators: Doctors Tunde Peto and Anna Boixadera

Screening

Diabetic retinopathy screening at a UK district general hospital. F. Blain, S. Shafquat

Is it safe to increase diabetic retinopathy screening interval in patients with no/background diabetic retinopathy? H. Chambers, S.B. Balu, H.W . Wharton, P.M.D. Dodson, JMG. Gibson

Epiretinal membrane in diabetic retinopathy screening. N. Bilkhu, A.D. Wright, A. Farnsworth, S. Osei-Amoako, P.M. Dodson

Is arbitration of all abnormal grades valuable in retinopathy grading quality assurance? L. Quant, A.P. Mills, A. Hamid, H. Wharton, M. Clarke, PM. Dodson

Evaluation of automated image analysis software for the detection of diabetic retinopathy to reduce the ophthalmologist workload. E. Soto-Pedre, A. Navea, J. Morales, S. Millan, M.C. Hernaez-Ortega, P. Perez, M.C. Desco

Review of change in referral rates to hospital eye services from a population based diabetic retinopathy screening service during the initial six years of service delivery. M. Morgan, M. Murphy

Are diabetic retinopathy virtual clinics safe? O. Giasin, J. Myerscough, C. James,


Y. Osoba

Relationship between time from diagnosis of diabetes to screening and grading outcome. S. Aldington, I.M. Stratton, M. Histed, P. H. Scanlon

Accuracy of glaucoma suspect referrals from diabetic retinopathy screening. T. Peto, K. Balaskas, R. Puertas

NHS Diabetic Eye Screening Programme on-line Test and Training (TAT): past, present and future. S. Aldington, I.M. Stratton, D.J. Taylor, P.H. Scanlon

The influence risk communication tools on diabetes self management. N. Al-Athamneh, J. Sturt, I.M. Stratton, A. Lindenmeyer, P.H. Scanlon

Basic Research

Tear fluid proteomics multimarkers for diabetic retinopathy screening. A. Csutak, ZS. Torok, T. Peto, E. Csosz, A.M. Molnar, J. Tozser, A. Hajdu

Role of vascular endotelium growth factor (VEGF) and renin-аngiotenzin systems in patogenesis diabetic retinopathy. D. Lipatov, J.E. Bautina, M.V. Shestakova, A.G. Kuzmin, T.A. Chistjakov

VEGF levels in plasma in relation to platelet activation, glycaemic control and microvascular complications in type 1 diabetes mellitus. R. Schlingemann, C.J.F . Van Noorden, J.C.M. Meijers, W.M. Wiersinga

Diabetic Macular Oedema

Macular function: better than visual acuity for assessing diabetic maculopathy? A. Raj, J.N. Sahni, C. Campa, G. Czanner, R. Hagan, S.P. Harding

RELIGHT- ranibizumab treatment of diabetic macular oedema with bimonthly monitoring after initial treatment. I. Pearce, The RELIGHT Study group

Automated detection of leakage sites in fundus fluorescein angiography for diabetic maculopathy. M.T. Kwong, Y. Zheng, D. Parry, J.N. Sahni, A. Raj, S.P. Harding

Epidemiology

Sixteen-year incidence of diabetic retinopathy and proliferative diabetic retinopathy in a nationwide cohort of young Danish type 1 diabetic patients. R. B. Pedersen, M.L. Rasmussen, T. Peto, J. Grauslund

Non-Swedish origin may be a risk factor for diabetic retinopathy at diagnosis in Scania, Sweden, in 2008-2012. C. Gustavsson, M. Dorkhan, L. Groop

Staging of diabetic retinopathy upon initial presentation in Saudi Arabia. R.M. Gandour, S. Waheeb, I.A. Alhabli, A.K. Baothman

The effects of combined therapy with metformine and sulfonylurea on clinical characteristics of metabolic syndrome in type 2 diabetes mellitus. M. Carcani, S. Carcani, M. Keci

2.45 – 3.00: Coffee to be served

Session 4: Pathophysiology of Diabetic Eye Disease

Chairs: Professors Alan Stitt and Toke Bek

3.00 – 3.15: Loss of protein tyrosine phosphatase 1b increases IGF-i receptor tyrosine phosphorylation but does not rescue retinal defects in IRS2-deficient mice. Ángela M. Valverde, Jesús Revuelta-Cervantes, Lorena Menes, Águeda González-Rodríguez, Virginia Pardo, Pedro de la Villa, Deborah J Burks, Ana I. Arroba
3.15 - 3.30: Morphological and functional characterisation of retinal neurodegeneration in DB/DB mice. P. Bogdanov, L. Corraliza , A.R. Rodrigues-Carvalho, J. Garcia-Arumí, R. Simó, C. Hernández

3.30 – 3.45: Mesenchymal stem cell-derived microvesicles induce pericyte destabilisation in diabetic-like conditions. E. Beltramo, E. Berrone, T. Lopatina, M. Porta

3.45 – 4.00: Vitreous TIMP-1 levels associate with neovascularisation and TGF-β2 levels in the clinical course of proliferative diabetic retinopathy. I. Vogels, R.J. Van Geest, I. Klaassen, S.Y. Lesnik-Oberstein, R. Goldschmeding, C.J.F. Van Noorden, R.O. Schlingemann

4.00 – 4.45: Eva Kohner lecture: Professor Francesco Bandello, Italy

Introduced by Professor Simon Harding

4.45 – 5.30: Annual General Meeting

Moderator: Dr Tunde Peto

Gala dinner: 7.30 for 8.00 at World Trade Centre



25th May 2013, Saturday

Session 5: Roundtable 2: Fenofibrate in Diabetic Eye Disease

Chairs: Professors Massimo Porta and Peter Scanlon

9.00 - 9.15: Simon Harding: Evidence from clinical trials

9.15 – 9.35: Rafael Simo: Potential mechanisms

9.35 – 9.50: Paul Dodson: Implications in clinical practice

9.50 – 10.00: Discussion



Session 6: New Insights for Treatment of Diabetic Retinopathy

Chairs: Dr Cristina Hernández and Professor Edoardo Midena

10.00 – 10.15: Effect of fenofibrate on retinal neurodegeneration in DB/DB mice. L. Corraliza, P. Bogdanov, A.R. Rodrigues-Carvalho, J. Garcia-Arumí, C. Hernández, R. Simó

10.15 – 10.30: Beneficial effects of somatostatin in cellular viability of rcg5 cells and retinal explants under diabetic conditions: possible role of protein tyrosine phosphatase 1B. Ana I Arroba, Deborah J Burks, Cristina Hernández-Pascual, Rafael Simó and Angela M Valverde


10.30 – 10.45: The neuroprotective drugs somatostatin and brimonidine do not show adverse effects on human retinal pericytes. T. Lopatina, E. Beltramo, M. Porta

10.45 – 11.00: Novel nonpeptide superoxide dismutase mimetics attenuate hydrogen peroxide-induced damage to retinal ganglion cells and human retinal pericytes. A. Oknianska, U. Popowska, M. Gorska, N. Knap, A. Daca, S .P. Harding, M. Wozniak

11.00 – 11.15: A shift in the balance of VEGF and CTGF by bevacizumab causes the angio-fibrotic switch in proliferative diabetic retinopathy. M. Dallinga, I. Klaassen, R.J. Van Geest, S.Y. Lesnik-Oberstein, R. Goldschmeding, C.J.F. Van Noorden, R.O. Schlingemann

11.15 – 11.45: Coffee



Session 7: The Diabetic Eye

Chairs: Professor Elizabeth Agardh and Dr Luis Arias

11.45 – 12.00: Estimating the interval preceding diagnosis of type 2 diabetes from the time-course of retinopathy prevalence. M. Porta, G. Curletto, E. Coppo, A. Raviolo, E. Sitia, S. Albani, P. Dalmasso

12.00 – 12.15: Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular oedema. V. Chong, P. Mitchell

12.15 – 12.30: Patient-reported visual function in diabetic macular oedema: 36-month results from the RESTORE extension study. P. Massin, P. Mitchell, J. Petrillo, C. D. Coon, A. Ferreira, N. Bressler

12.30 – 12.45: An evaluation of ophthalmic photographic diabetic review (OPDR) with two fields digital photography for diabetic maculopathy (M1) and 4 year follow-up. H. Fellows, M. Shah, A. Hamid, L. Quant, M. Clarke, P.M. Dodson

12.45 – 1.00: Clinical and demographic features of patients with diabetic macular oedema. F. Afshar, D. Baumgardt, C. Bailey

1.00: Best poster prize ceremony and closing remarks



Professor Massimo Porta


The database is protected by copyright ©dentisty.org 2016
send message

    Main page